Wave Life Sciences (WVE) Stock Price, News & Analysis

Company Overview

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, a RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; siRNA clinical candidate for the treatment of obesity and other metabolic disorders; WVE-N531, a exon skipping oligonucleotide for the treatment of duchenne muscular dystrophy; and WVE-003, an antisense silencing oligonucleotide for the treatment of Huntington's disease (HD). The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD. Wave Life Sciences Ltd. was incorporated in 2012 and is based in Singapore.

Key Stats

• Today's Range: $7.85 to $8.23
• 50-Day Range: $5.48 to $11.23
• 52-Week Range: $4.25 to $16.74
• Volume: 154,442 shs
• Average Volume: 1.24 million shs
• Market Capitalization: $1.25 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $21.17
• Consensus Rating: Buy

Wave Life Sciences Stock Analysis - MarketRank™

Wave Life Sciences scored higher than 86% of companies evaluated by MarketBeat, and ranked 93rd out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Wave Life Sciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 10 buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Wave Life Sciences has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Wave Life Sciences are expected to grow in the coming year, from ($1.14) to ($1.06) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Wave Life Sciences is -7.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Wave Life Sciences is -7.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Wave Life Sciences has a P/B Ratio of 20.42. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

10.79% of the float of Wave Life Sciences has been sold short.

Short Interest Ratio / Days to Cover

Wave Life Sciences has a short interest ratio ("days to cover") of 9.6.

Change versus previous month

Short interest in Wave Life Sciences has recently increased by 17.40%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Wave Life Sciences does not currently pay a dividend.

Dividend Growth

Wave Life Sciences does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.8 / 5
• Environmental Score: -0.58

Percentage of Shares Shorted

10.79% of the float of Wave Life Sciences has been sold short.

Short Interest Ratio / Days to Cover

Wave Life Sciences has a short interest ratio ("days to cover") of 9.6.

Change versus previous month

Short interest in Wave Life Sciences has recently increased by 17.40%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 2.7 / 5
• News Sentiment: 0.86

News Sentiment

Wave Life Sciences has a news sentiment score of 0.86. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.73 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 25 news articles for Wave Life Sciences this week, compared to 6 articles on an average week.

MarketBeat Follows

Only 3 people have added Wave Life Sciences to their MarketBeat watchlist in the last 30 days. This is a decrease of -40% compared to the previous 30 days.

Company Ownership

• Score: 4.2 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Wave Life Sciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,720,154.00 in company stock.

Percentage Held by Insiders

29.10% of the stock of Wave Life Sciences is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

89.73% of the stock of Wave Life Sciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

WVE Stock Analysis - Frequently Asked Questions

How have WVE shares performed this year?

Wave Life Sciences' stock was trading at $12.37 at the beginning of the year. Since then, WVE shares have decreased by 34.0% and is now trading at $8.1670.
View the best growth stocks for 2025 here.

How were Wave Life Sciences' earnings last quarter?

Wave Life Sciences Ltd. (NASDAQ:WVE) posted its quarterly earnings results on Tuesday, March, 4th. The company reported $0.17 EPS for the quarter, beating the consensus estimate of ($0.17) by $0.34. The business had revenue of $83.75 million for the quarter, compared to analysts' expectations of $25.60 million. Wave Life Sciences had a negative net margin of 66.50% and a negative trailing twelve-month return on equity of 280.57%.
Read the conference call transcript.

Who are Wave Life Sciences' major shareholders?

Top institutional shareholders of Wave Life Sciences include Emerald Advisers LLC (2.04%), Moody Aldrich Partners LLC (0.29%), Principal Financial Group Inc. (0.20%) and Bank of New York Mellon Corp (0.16%). Insiders that own company stock include Ra Capital Management, LP, Plc Gsk, Paul Bolno, Chandra Vargeese, Kyle Moran, Christian O Henry and Chris Francis.
View institutional ownership trends.

How do I buy shares of Wave Life Sciences?

Shares of WVE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Wave Life Sciences own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Wave Life Sciences investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Meta Platforms (META), Tesla (TSLA), JPMorgan Chase & Co. (JPM), Intel (INTC) and Netflix (NFLX).

Company Calendar

• Last Earnings: 3/04/2025
• Today: 5/04/2025
• Next Earnings (Estimated): 5/08/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:WVE
• CIK: 1631574
• Web: www.wavelifesciences.com
• Phone: (656) 236-3388
• Fax: 617-949-2901
• Employees: 240
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $21.17
• High Stock Price Target: $36.00
• Low Stock Price Target: $10.00
• Potential Upside/Downside: +161.3%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 12 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($0.79)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-57,510,000.00
• Net Margins: -66.50%
• Pretax Margin: -265.84%
• Return on Equity: -280.57%
• Return on Assets: -52.90%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.90
• Quick Ratio: 1.90

Sales & Book Value

• Annual Sales: $108.30 million
• Price / Sales: 11.52
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.40 per share
• Price / Book: 20.25

Miscellaneous

• Outstanding Shares: 154,090,000
• Free Float: 108,137,000
• Market Cap: $1.25 billion
• Optionable: Optionable
• Beta: -0.91